Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac
New Research Reports for Oracle, Chubb, AstraZeneca & Others
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.
AstraZeneca (AZN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Anglo-Swedish group to make and supply beta-blocker to Italian drugmaker Recordati
On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).
This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.